Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3780 Target Snapshot

Small conductance calcium-activated potassium channel protein 3 · SINGLE PROTEIN · Rattus norvegicus

123Compounds
12Assays
4Approved Drugs
122.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P70605. Use UniProt P70605 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P70605 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Small conductance calcium-activated potassium channel protein 3 as ChEMBL target CHEMBL3780, mapped to UniProt P70605. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Small conductance calcium-activated potassium channel protein 3
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-14
ChEMBL target ID
CHEMBL3780
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P70605
Small conductance calcium-activated potassium channel protein 3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Small conductance calcium-activated potassium channel protein 3 is the right protein anchor across sources, using UniProt P70605 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSmall conductance calcium-activated potassium channel protein 3
UniProt AccessionP70605
Component TypeProtein
Sequence Length732 aa

Small conductance calcium-activated potassium channel protein 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Small conductance calcium-activated potassium channel protein 3, mapped to UniProt P70605. Sequence length is 732 aa.

Mapped IDP70605
Review nameSmall conductance calcium-activated potassium channel protein 3
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

4
Approved
Assay Mix

Activity Type Distribution

IC5069.0
KI12.0
KD41.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL420873 9.37 Kd 0.43 Preclinical
CHEMBL420873 8.85 Ki 1.4 Preclinical
CHEMBL2391662 8.77 IC50 1.7 Preclinical
CHEMBL117908 8.74 Ki 1.8 Preclinical
CHEMBL2391665 8.64 IC50 2.3 Preclinical
CHEMBL2391673 8.59 IC50 2.6 Preclinical
CHEMBL117908 8.57 Kd 2.7 Preclinical
CHEMBL185463 8.57 IC50 2.7 Preclinical
CHEMBL2391668 8.52 IC50 3.0 Preclinical
CHEMBL2391675 8.52 IC50 3.0 Preclinical
Distribution

pChEMBL Value Distribution

6
5.0
6
5.5
11
6.0
17
6.5
15
7.0
21
7.5
20
8.0
9
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DEQUALINIUM CHLORIDE
CHEMBL121663
Assay Landscape

Assay Landscape

12
Total Assays
106
Tested Compounds
1
Assay Types
Binding — 12 assays, 106 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 49 6.5
single protein format 4 57 7.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine